Recombinant Human Apolipoprotein A-I (ApoA-I)

Recombinant Human Apolipoprotein AI (ApoAI) is widely used in research due to its central role in reverse cholesterol transport, its antiinflammatory and antioxidant properties, and its relevance in cardiovascular and cancer biology.

Key reasons to use recombinant ApoAI in research applications:

• Reverse Cholesterol Transport (RCT): ApoAI is the main protein component of highdensity lipoprotein (HDL) and is essential for mediating the efflux of cholesterol from peripheral tissues to the liver for excretion, a process that protects against atherosclerosis. Recombinant ApoAI enables controlled studies of RCT mechanisms and HDL biogenesis in vitro and in vivo.

• Atherosclerosis and Cardiovascular Disease Models: Recombinant ApoAI and its variants (such as ApoAI Milano) have been shown in animal and human studies to reduce atherosclerotic plaque burden, promote plaque regression, and improve HDL functionality. This makes it a valuable tool for preclinical and translational research on cardiovascular therapies.

• Antiinflammatory and Antioxidant Effects: ApoAI exhibits antiinflammatory actions by modulating immune cell activation, inhibiting proinflammatory cytokine production, and reducing oxidative stress in vascular tissues. These properties are relevant for studying inflammationrelated diseases and vascular biology.

• Cancer Research: Altered ApoAI levels are associated with cancer risk and progression. ApoAI has been implicated in tumor suppression through immune modulation and antiinflammatory mechanisms, making recombinant ApoAI useful for investigating cancer pathogenesis and potential therapeutic strategies.

• Biomarker and Functional Studies: Recombinant ApoAI is used as a standard or control in assays measuring HDL function, cholesterol efflux capacity, and as a biomarker in clinical and translational studies.

• Therapeutic Development: Recombinant ApoAI is being explored in clinical trials as a therapeutic agent for cardiovascular disease, providing a platform for drug development and mechanistic studies.

• Protein Engineering and StructureFunction Analysis: Recombinant production allows for sitedirected mutagenesis and structural studies, facilitating the investigation of ApoAI’s functional domains and interactions with lipids and cellular receptors.

In summary, recombinant human ApoAI is a versatile tool for research in lipid metabolism, cardiovascular disease, inflammation, immunity, and cancer, enabling mechanistic studies, therapeutic development, and biomarker discovery under controlled experimental conditions.

Yes, recombinant human Apolipoprotein AI (ApoAI) can be used as a standard for quantification or calibration in ELISA assays, provided it is properly validated for your specific assay system. Recombinant ApoAI expressed in E. coli is commonly used as a calibrator in commercial ELISA kits, and its standard curves are shown to be parallel and comparable to those generated with natural human ApoAI.

Key considerations and supporting details:

• Assay Calibration: ELISA kits designed for ApoAI quantification often use recombinant human ApoAI as the reference standard. These kits demonstrate that standard curves generated with recombinant ApoAI are linear and parallel to those obtained with natural ApoAI, allowing for accurate quantification of both recombinant and endogenous protein in biological samples.

• Specificity: Most sandwich ELISA kits for ApoAI are validated to recognize both natural and recombinant forms of the protein, ensuring that recombinant ApoAI is suitable for use as a standard.

• Purity and Activity: Recombinant ApoAI used as a standard should be of high purity (typically >95% by SDSPAGE and HPLC) and, while biological activity is not always required for ELISA calibration, the protein should be structurally intact and free from interfering contaminants.

• Validation: Before using recombinant ApoAI as a standard in your own custom or inhouse ELISA, it is essential to validate that the antibody pair in your assay recognizes the recombinant form equivalently to the native protein. This can be confirmed by generating standard curves and comparing their slopes and linearity with those from natural ApoAI.

• Preparation: Recombinant ApoAI should be reconstituted and diluted in the same buffer or diluent used for your assay standards to ensure consistency and minimize matrix effects.

• Limitations: Always ensure the recombinant standard is compatible with your assay’s detection antibodies and that it does not contain tags or modifications that could affect antibody binding. Some recombinant preparations may lack posttranslational modifications present in native ApoAI, but this typically does not affect ELISA quantification unless the antibodies are modificationspecific.

Best practices:

• Use recombinant ApoAI from a reliable source with documented purity and sequence.
• Validate the standard curve in your assay system, especially if using custom antibodies.
• Prepare and store standards according to recommended protocols to maintain protein integrity.

In summary, recombinant human ApoAI is widely accepted and scientifically appropriate as a standard for ELISA quantification, provided assayspecific validation is performed.

Recombinant Human Apolipoprotein AI (ApoAI) has been validated in published research for a broad range of scientific and therapeutic applications, primarily in cardiovascular, metabolic, neurological, immunological, and biochemical studies.

Key validated applications include:

• Reverse Cholesterol Transport (RCT) and HDL Biogenesis: Recombinant ApoAI is widely used to study and enhance RCT, a process critical for removing excess cholesterol from peripheral tissues and forming highdensity lipoprotein (HDL) particles. It serves as a scaffold protein for reconstituted HDL (rHDL) particles in vitro, which are then used in cholesterol efflux assays and lecithin:cholesterol acyltransferase (LCAT) activity assays.

• Cardiovascular Research and Therapeutics: Recombinant ApoAI has been validated in animal models and clinical studies for its cardioprotective effects, including improving endothelial function, reducing inflammation, and promoting cholesterol efflux. It is used in preclinical and clinical trials to assess its potential to reduce cardiovascular disease (CVD) risk and events, such as after acute myocardial infarction.

• Immunomodulation and Inflammation: Studies have demonstrated that ApoAI exhibits antiinflammatory and immunemodulatory properties, including inhibition of complement activation, reduction of proinflammatory cytokine production, and modulation of immune cell activation and migration. It has been used in models of sepsis, autoimmune disease, and cancer to investigate these effects.

• Cancer Research: Recombinant ApoAI has been validated for its tumor suppressive activity in vitro and in vivo, including inhibition of apoptosis, reduction of oxidative stress, and modulation of immune responses in the tumor microenvironment.

• Neurological Disorders and Biomarker Studies: ApoAI is used in research on Alzheimer’s disease (AD) and other neurological conditions, both as a biomarker and as a therapeutic agent. Exogenous administration in animal models has shown reduction of amyloidbeta (Aβ) levels, alleviation of neuroinflammation, and prevention of cognitive deficits.

• Biochemical and Structural Studies: Recombinant ApoAI is employed in structural biology to elucidate its conformation, lipidbinding properties, and interactions with cellular receptors and transporters (e.g., ABCA1). It is also used in protein engineering and foam fractionation studies to optimize production and purification protocols.

• Drug Delivery and Protein Solubilization: rHDL particles formed with recombinant ApoAI are validated as carriers for drug delivery and as substrates for solubilizing transmembrane proteins in biochemical assays.

Experimental protocols and assays where recombinant ApoAI is validated:

• Cholesterol efflux assays (using ABCA1expressing cells)
• LCAT activity assays
• SDSPAGE and Western blotting for protein characterization
• ELISA for quantification and biomarker studies
• Cellular binding assays (e.g., liver cell binding)
• In vivo administration in animal models for therapeutic evaluation

Summary Table of Validated Applications

These applications are supported by peerreviewed studies and validated experimental protocols, demonstrating the versatility of recombinant human ApoAI in both basic and translational research.

To reconstitute and prepare Recombinant Human Apolipoprotein AI (ApoAI) for cell culture experiments, dissolve the lyophilized protein in sterile buffer—commonly phosphatebuffered saline (PBS) or sterile deionized water—to a concentration suitable for your application, typically ranging from 100 μg/mL to 1 mg/mL.

Stepbystep protocol:

• Reconstitution:

  • Add sterile PBS or sterile deionized water directly to the lyophilized ApoAI protein.
  • For most cell culture applications, a final concentration of 100 μg/mL in PBS is recommended. Some protocols use 400 μg/mL in sterile deionized water, or 1 mg/mL in water.
  • Gently mix by pipetting or slow vortexing until fully dissolved. Avoid vigorous agitation to prevent protein denaturation.

• Sterility:

  • Use sterile reagents and aseptic technique throughout to prevent contamination.
  • If necessary, filter the reconstituted solution through a 0.2 μm sterile filter.

• Storage:

  • Store the reconstituted ApoAI at 2–8 °C for up to one month, or at –20 °C to –70 °C for longer periods.
  • Avoid repeated freezethaw cycles to maintain protein integrity.

• Preparation for cell culture:

  • Dilute the stock solution to the desired working concentration using sterile cell culture medium or buffer.
  • If using for rHDL formation, incubate ApoAI with phospholipids (e.g., DMPC) and sonicate as needed to clarify the solution and promote rHDL assembly.

Additional notes:

• ApoAI is structurally resilient and refolds to its native conformation after denaturation, so gentle handling is sufficient for reconstitution.
• Confirm protein concentration using a suitable assay (e.g., BCA assay) before use.
• Ensure low endotoxin levels if using in sensitive cell culture systems; purification protocols typically yield low endotoxin ApoAI.

Summary Table:

This protocol ensures that ApoAI is properly reconstituted and prepared for use in cell culture experiments, maintaining its biological activity and structural integrity.